Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
University of Rochester
Summary
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is stage IV. Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.
Description
PRIMARY OBJECTIVE: I. To identify multiple distinct diagnostic subtypes within the syndrome of CC as defined by host characteristics (e.g. cachexia symptoms, physical activity, physical function, blood biomarkers including hemoglobin and albumin, and body composition) at baseline and change in these factors over time in patients with cancer at high risk for CC. SECONDARY OBJECTIVES: I. To determine the association of each CC phenotype with overall survival. II. To validate CC diagnostic phenotypes developed in a separate, independent cachexia observational study performed by our collaborato…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Have a primary diagnosis of unresectable or stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer * Note: Patients do not need to have cachexia to be eligible * Plan to start first-line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, interventional clinical trial) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks. * NOTE: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant treatment and have since recurred ar…
Interventions
- ProcedureBiospecimen Collection
Undergo collection of blood and archived tumor samples
- ProcedureComputed Tomography
Undergo CT or PET/CT scan
- OtherElectronic Health Record Review
Medical records reviewed
- OtherMedical Device Usage and Evaluation
Wear actigraph
- OtherPhysical Performance Testing
Undergo physical function tests
- ProcedurePositron Emission Tomography
Undergo PET/CT scan
- OtherSurvey Administration
Locations (225)
- Mercy Hospital Fort SmithFort Smith, Arkansas
- Rocky Mountain Cancer Centers-AuroraAurora, Colorado
- Boulder Community Foothills HospitalBoulder, Colorado
- Rocky Mountain Cancer Centers-BoulderBoulder, Colorado
- Rocky Mountain Cancer Centers - CentennialCentennial, Colorado
- The Women's Imaging CenterDenver, Colorado